#News for #Investors and #Media: At #TLM26 we’re unveiling our latest advancements across our hepatology pipeline for chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and alcohol-related liver disease (ALD).
Find out more in the press release: gsk.to/4egVmcZ
#TLM26
Find out more in the press release: gsk.to/4egVmcZ
#TLM26
0:07